Cost-effectiveness analysis of tension-free vaginal tape vs burch colposuspension for female stress urinary incontinence in the USA.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25

Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84

Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology (2012) 2.36

HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. J Acquir Immune Defic Syndr (2012) 2.34

The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol (2013) 2.33

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol (2012) 2.26

Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. Urology (2013) 2.20

One-arm, open-label, prospective, cohort field study to assess the safety and efficacy of the PrePex device for scale-up of nonsurgical circumcision when performed by nurses in resource-limited settings for HIV prevention. J Acquir Immune Defic Syndr (2013) 2.18

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2012) 2.11

Current role for combination therapy in male LUTS. Arch Esp Urol (2010) 2.03

Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet (2012) 2.00

Re: monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. J Urol (2012) 1.98

Noninvasive methods to evaluate bladder obstruction in men. Int Braz J Urol (2013) 1.98

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol (2007) 1.96

Three year results of the prostatic urethral L.I.F.T. study. Can J Urol (2015) 1.92

Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol (2005) 1.72

Ten-year experience with transvaginal vesicovaginal fistula repair using tissue interposition. J Urol (2003) 1.72

Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71

Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65

Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy. Eur Urol (2012) 1.65

Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol (2010) 1.63

Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62

Aqueous humor dynamics: a review. Open Ophthalmol J (2010) 1.55

A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol (2004) 1.52

Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype. J Urol (2004) 1.50

High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology (2004) 1.50

Association of urological symptoms and chronic illness in men and women: contributions of symptom severity and duration--results from the BACH Survey. J Urol (2008) 1.49

Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49

Concordance of near infrared spectroscopy with pressure flow studies in men with lower urinary tract symptoms. J Urol (2010) 1.48

Trends and inequalities in the surgical management of ureteric calculi in the USA. BJU Int (2013) 1.47

Glaucoma drainage implants: a critical comparison of types. Curr Opin Ophthalmol (2006) 1.47

International variation in artificial urinary sphincter use. Urology (2012) 1.46

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol (2008) 1.43

Management of anastomotic stricture after artificial urinary sphincter placement in patients who underwent salvage prostatectomy. Urology (2013) 1.41

Patient perceived outcomes of treatments used for interstitial cystitis. Urology (2008) 1.40

The use of mesh in vaginal prolapse repair: do the benefits justify the risks? Curr Opin Urol (2010) 1.39

Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. J Urol (2013) 1.37

Re: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. J Urol (2012) 1.37

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials (2003) 1.33

Varicocele as a risk factor for androgen deficiency and effect of repair. BJU Int (2011) 1.29

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26

Interstitial cystitis and panic disorder: a potential genetic syndrome. Arch Gen Psychiatry (2004) 1.20

Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol (2008) 1.19

Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups. Neurourol Urodyn (2011) 1.18

Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol (2009) 1.18

Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol (2009) 1.18

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol (2005) 1.17

Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int (2009) 1.17

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol (2008) 1.16

Temporal trends in adoption of and indications for the artificial urinary sphincter. J Urol (2009) 1.15

Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int (2012) 1.11

Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.10

Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int (2008) 1.09

Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome. Evid Based Complement Alternat Med (2005) 1.08

Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. Urology (2006) 1.08

Field study of adult male circumcision using the ShangRing in routine clinical settings in Kenya and Zambia. J Acquir Immune Defic Syndr (2014) 1.07

Re: Noninvasive methods to evaluate bladder obstruction in men. Int Braz J Urol (2013) 1.07

The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables. J Glaucoma (2013) 1.06

Evidenced-based comparison of aqueous shunts. Curr Opin Ophthalmol (2013) 1.06

The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. World J Urol (2006) 1.04

Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol (2012) 1.03

Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol (2011) 1.02

Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. Am J Ophthalmol (2008) 1.01

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol (2014) 1.00

Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int (2013) 1.00

Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer (2013) 0.99

Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Curr Urol Rep (2008) 0.99

Non-surgical adult male circumcision using the PrePex device: task-shifting from physicians to nurses. Afr J Reprod Health (2014) 0.98

The effects of acute and chronic psychological stress on bladder function in a rodent model. Urology (2011) 0.98

Bladder and urethral function in pelvic organ prolapsed lysyl oxidase like-1 knockout mice. BJU Int (2007) 0.97

Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy. Cancer (2008) 0.97

Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. BJU Int (2008) 0.96

Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol (2012) 0.96

Cochlin, intraocular pressure regulation and mechanosensing. PLoS One (2012) 0.96

Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol (2013) 0.95

The Next Generation in Laser Treatments and the Role of the GreenLight High-Performance System Laser. Rev Urol (2006) 0.94

High-power 532 nm laser prostatectomy: an update. Curr Opin Urol (2010) 0.94

Decreasing electrosurgical transurethral resection of the prostate surgical volume during graduate medical education training is associated with increased surgical adverse events. J Urol (2010) 0.94

Hypothesis-independent pathway analysis implicates GABA and acetyl-CoA metabolism in primary open-angle glaucoma and normal-pressure glaucoma. Hum Genet (2014) 0.93

Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology (2011) 0.93

GreenLight laser for prostates over 100 ml: what is the evidence? Curr Opin Urol (2016) 0.92